RA Capital and D. E. Shaw lead the July 21-28 whale tape

RA Capital and D. E. Shaw lead the July 21-28 whale tape

RA Capital's 37.9% Artiva stake and D. E. Shaw's 7.1% Gossamer filing led the US-manager tape, while Cevian's $1.67B Smith & Nephew position and a ReNew bid revision supplied the week's biggest special-situation signals.

What actually changed

Data cutoff: July 28, 2026, 8:00 a.m. channel time.
RA Capital's 37.9% Artiva position, D. E. Shaw's 7.1% Gossamer disclosure and Olesen's 10.1% Solitron filing supplied the clearest US-manager signals in the July 21-28 window. Cevian Capital's 14.18% Smith & Nephew position was the largest disclosed dollar commitment in this selected filing set, while a Canada Pension Plan-led consortium raised its non-binding ReNew Energy Global proposal to $7.02 per share. 1 2 3
The selected set also includes deal and foreign institutional filings because they change control, voting rights or transaction odds. They are useful context, but they should not be mistaken for US hedge-fund trades. The other important distinction is form type. ALOT produced a clean 13D exit after Askeladden reduced below 5%, while PENG disclosed a deal-linked transfer of preferred shares and BlackRock's APLD and TEAM filings mapped passive holdings measured at June 30. Those are meaningful ownership changes, but they do not carry the same directional signal as a cash purchase.

The ranked whale tape

RankTickerWhale or filerNew disclosure and timingDirectional read
1SNNCevian CapitalCevian reports 119,179,419 Smith & Nephew ordinary shares, or 14.18%, with about $1,673,390,427 of aggregate consideration. The event date is July 23; the filing became available July 27. 1Clear accumulation and the strongest dollar commitment in this set. The filing gives the position's total cost, not a one-week purchase delta, so the next amendment matters more than the headline percentage.
2ARTVRA Capital ManagementRA Capital and affiliated funds report 18,415,956 Artiva shares, or 37.9%, including 17,242,483 shares in RA Capital Healthcare Fund. The fund bought multiple open-market blocks from June 16 through July 23 at prices from $8.62 to $10.00; the amendment was available July 23. 2Continuing biotech accumulation, but not all reported exposure is immediately exercisable: 2,170,138 pre-funded warrant shares sit behind a 9.99% blocker.
3RNWCanada Pension Plan Investment Board and consortiumThe reporting group says it beneficially owns 88,846,844 ReNew Energy Global shares, or 34.4% of voting rights, including 76,501,166 shares and rights tied to 12,345,678 additional shares. On July 27 it raised its cash proposal to $7.02 per share and called it its best and final non-binding offer. 3A deal catalyst, not an ordinary stock purchase. The proposal can still fail because no definitive transaction agreement exists.
4PENGSK Telecom, Astra AI Infra and SK hynixAstra agreed on July 27 to sell all 200,000 Penguin Solutions convertible preferred shares to SHIFTIX1, a wholly owned SK hynix subsidiary, for $380,296,000. The preferred block represents 6,096,103 potential ordinary shares, or 10.3%, and carries board nomination, consent, pro rata and registration rights. The filing became available July 28. 4A control-rights transfer with closing conditions and regulatory approvals. It is a holder reset, not evidence that public-market investors are buying PENG common stock.
5SODIOlesen Value FundOlesen reports 216,508 Solitron Devices shares, or about 10.1%, acquired in open-market transactions for about $811,460. The filing also reports recent sales, including 3,366 shares at $29.71 on July 20; the event date is July 21 and the filing was available July 23. 5A real accumulated position with a mixed tape. Olesen says it may discuss shareholder value creation, but the recent sale means this is not a clean add signal.
6ALOTAskeladden Capital ManagementAskeladden and Samir Patel report only 32,354 AstroNova shares, or 0.4%, after reducing below the 5% threshold. The filing is explicitly an exit Schedule 13D. They support AstroNova's announced Arcline acquisition and report about $326,260 of historical purchase cost; event and filing date were July 23. 6The cleanest sell-side signal of the week. It reads as a deal-position exit rather than a fresh bearish call on the company.
7NIUGlory Achievement Fund, Bull Group and BULL TRUSTThe group reports 65,693,947 Niu Technologies ordinary shares, or 41.9% on an as-converted basis. Glory Achievement Fund bought 837,918 ADSs, representing 1,675,836 Class A shares, for about $2.1 million from June 25 through July 23; the amendment was available July 24. 7A continuing buy signal, with a capital-structure warning attached. Class B shares carry four votes each, so the 41.9% class figure is not a standalone voting-power percentage.
8GOSSD. E. Shaw-affiliated entitiesD. E. Shaw entities report shared power over 34,609,565 Gossamer Bio shares, or 7.1%, in an amendment available July 24. The filing references a transaction support agreement, voting agreement, senior secured convertible notes due 2030 and a purchase warrant agreement. 8A restructuring-linked ownership disclosure. The agreements matter, but this amendment should not be read as a fresh open-market buy without a new share-count or trade disclosure.

The passive manager map

BlackRock's July 27 amendments add two large ownership markers, both based on June 30 holdings rather than a disclosed weekly trade. BlackRock reports 12,199,793 Applied Digital shares, or 4.3%, and 11,611,358 Atlassian Class A shares, or 7.3%. Citadel-linked entities also report 9,595,542 Bitdeer Class A shares, or 4.8%, with the holdings measured as of the July 27 market open. None of these filings gives a purchase price or a change in investment intent. 9 10 11
For retail traders, these are exposure maps, not copy-trade entries. A 13G/A tells you who crossed or updated a reporting threshold; without the prior share count or a transaction schedule, it does not tell you whether the manager bought this week, held steady, or simply crossed the reporting line after the issuer's share count changed.

Where the signals cluster

Healthcare and biotech account for several of the more concentrated disclosures. RA Capital's 37.9% Artiva position and D. E. Shaw's 7.1% Gossamer position both sit inside deal, financing or ownership structures where dilution and contractual rights matter as much as the headline percentage. The common signal is concentrated exposure, not a broad sector allocation call. 2 8
The other cluster is special situations: RNW's revised proposal, PENG's preferred transfer and ALOT's exit all depend on a transaction or corporate action. Those filings can move prices quickly, but their outcomes depend on approvals, closing conditions, definitive agreements or merger completion. They are less portable than a simple open-market buy.

Retail follow-up list

  1. SNN: Look for a subsequent Cevian amendment that changes the 119.2 million-share position or adds explicit governance language. The current filing establishes size and funding, not the next catalyst.
  2. ARTV: Track whether RA Capital continues buying and whether the 9.99% blocker changes the fund's ability to exercise warrants.
  3. RNW: The next hard data point is a definitive agreement. Until then, $7.02 is a non-binding proposal, even though the consortium calls it best and final.
  4. PENG: Watch for closing confirmation and the transfer of the investor-agreement rights to SK hynix's subsidiary.
  5. SODI and NIU: Keep the direction, but keep the caveats. SODI includes recent selling, while NIU's class ownership percentage does not equal voting control.
  6. ALOT and GOSS: Treat ALOT as an exit and GOSS as a financing-linked ownership update. Neither is a clean new-buy signal.
This is a filing-based market digest, not investment advice.

Related content

  • Sign in to comment.
More from this channel